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Abstract The therapeutic use of bacteriophages has seen a
renewal of interest blossom in the last few years. This
reversion is due to increased difficulties in the treatment of
antibiotic-resistant strains of bacteria. Bacterial resistance
to antibiotics, a serious problem in contemporary medicine,
does not implicate resistance to phage lysis mechanisms.
Lytic bacteriophages are able to kill antibiotic-resistant
bacteria at the end of the phage infection cycle. Thus, the
development of phage therapy is potentially a way to
improve the treatment of bacterial infections. However,
there are antibacterial phage therapy difficulties specified
by broadening the knowledge of the phage nature and
influence on the host. It has been shown during experi-
ments that both innate and adaptive immunity are involved
in the clearance of phages from the body. Immunological
reactions against phages are related to the route of
administration and may vary depending on the type of
bacterial viruses. For that reason, it is very important to test
the immunological response of every single phage, par-
ticularly if intravenous therapy is being considered. The
lack of these data in previous years was one of the reasons
for phage therapy abandonment despite its century-long
study. Promising results of recent research led us to look
forward to a phage therapy that can be applied on a larger
scale and subsequently put it into practice.
History of Bacteriophage
The history of phage therapy could be separated into four
timespans, according to Summers et al. [48].
Early Enthusiasm
Bacteriophages were discovered by English microbiologist
Twort in 1915 [1] but ‘‘the bacteriophage phenomenon’’
era began after publication in 1917 by a French-Canadian
microbiologist Felix d’Herelle. During his investigations,
he observed ‘‘invisible microbes’’ in filtrates of stool from
patients suffering from dysentery that were ‘‘antagonistic’’
to bacteria. He surmised that this filterable virus, ‘‘ultra-
viruses,’’ was a cofactor of bacterial infection. However, he
proved that phage titers increased in disease progression
and peaked during recovery. After those successes,
d’Herelle branched out his investigations on humans. At
first, he had tested the safety of phage suspension on
himself, his co-workers, and family, then on patients suf-
fering from ‘‘bacillary dysentery’’ and cholera (since
1919). After that, phages were applied as a therapy to
wound recovery. Another experiment that focused on the
healing value of phages investigated Salmonella galli-
narum as an infectious agent of avian typhosis (published
in 1926). This test also confirmed phage protection, as well
as it did against other species, like Pasteurella multocida
(bovine hemorrhagic septicaemia, published in the same
year). Nevertheless, the first publication about phage
therapy described the work of Bruynoghe and Maisin.
Their results were published in 1921 [1, 48].
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Critical Scepticism
Despite the fact that many early experiments of phage
therapy reported positive results, there were also some
disappointments. In 1934, a report was published in which
previously released data were criticized. In the author’s
opinion, the biological viral nature of phage was not known
well enough, both their strengths and limitations. More-
over, the report showed mistakes such as no standard in
phage preparation and no criteria to compare the investi-
gations’ results [1].
Abandonment
War World II and the discovery of antibiotics reversed
away the study in bacteriophage investigation, especially in
the USA. The effortlessness of production, broad spectrum
of activity, and stability in the preparation process were the
advantages of antibiotics. In Europe, by contrast, two
military-expanded countries (the Soviet Union and Ger-
many) used phages as a medical treatment for healing
wounds. In the Soviet Union, applications of phages were
mainly driven by cost-effective and ideational motives
(‘‘preponderance’’ of Soviet science over the capitalist
West) [47]. Moreover, The State Serum and Vaccine
Institute in Tbilisi, Georgia, founded, among others, by
d’Herelle was one of the major centres of phage therapy of
that time [49]. A curious about phage therapy is the fact
that the Pasteur Institute, the mother institution of
d’Herelle where he worked on bacteriophages, obtained
their bacterial viruses mainly from Russia or Georgia, even
at the present time [1].
Another reason of abandoning the bacteriophage therapy
in post-war time was the problem of phage-resistant bac-
teria, an unwittingness of pathogenic mechanisms in bac-
teria and of the nature of interactions between phage and
their host. This lack of knowledge also included DNA
restriction, an absence of models of animal diseases and
listed lapses in experimental design [2].
Recent Interest and Reappraisal
In the 1970s, in Pakistan several experiments of the use of
bacteriophages (prepared in the USSR), in the treatment of
cholera were sponsored by WHO [27, 29]. A conclusion of
these articles could be a statement that treatment of cholera
with bacteriophage is not as effective as therapy with
antibiotic (tetracycline); however, anti-cholera phage can
selectively reduce the majority of vibrios without inter-
fering with other intestinal microorganisms, and without
any noticeable toxic effect on the patient. Therefore, bac-
teriophage might be a helpful study instrument.
Another set of articles about phage therapy applied as
the treatment of diarrohea (models of mice and farm ani-
mals infected with Escherichia coli) concluded that bac-
teriophages could be employed both in treatment and
prophylaxis [41–44]. These works were the beginning of
western phage renaissance, which was propelled also by
the rich trove of Soviet and Polish work. Research in
Poland has been done mainly in connection with the
Hirszfeld Institute of Immunology and Experimental
Therapy in Wroclaw and has involved thousands of
patients. Furthermore, those studies are deemed to be one
of the most precisely documented [1]. In the whole history
of bacteriophage therapy, there were a lot of investigations
including also other etiological factors of diseases of both
animals and humans such as Acinetobacter, Burkholderia,
Citrobacter, Enterobacter, Enterococcus, Proteus, Pseu-
domonas, Shigella, Staphylococcus and Streptococcus
[47, 48]. The newest scientific research in the field of phage
therapy was presented in the following sections of this
article.
How Do Bacteriophages Kill Bacteria?
The increasing number of antibiotic-resistant bacterial
strains is a serious problem in contemporary medicine.
What is important is the fact that these bacteria do not
implicate resistance to phage lysis mechanisms. Lytic
bacteriophages are able to kill antibiotic-resistant bacteria
at the end of the phage infection cycle. Most of them utilize
two-component lysis systems to destroy a bacterial cell
wall in order to release progeny virions. Thus, the devel-
opment of phage therapy is a potential way to improve
treatment of bacterial infections.
The course of a replication cycle is the criterion to
divide bacteriophages into lytic and lysogenic ones. The
release of lytic phage progeny from infected cells requires
bacterial lysis. Scientific studies on phage lytic mecha-
nisms contribute to the development of phage therapy.
Some lytic bacteriophages use single proteins, amurins, to
inhibit the synthesis of peptidoglycan [56]. However, most
of them utilize two groups of proteins to kill the host cell.
The first ones, holins, synergize with the second ones,
endolysins, to cause lysis. Together, they make up the
holin–lysin systems [10, 23].
Holins are involved in the host cell lysis triggering
process. Their role is to perforate the host cytoplasmic
membrane and thus to cooperate with endolysins by giving
them an access to bacterial peptidoglycan. Therefore,
holins determine the time of bacterial lysis. Acting at a
precise time point, they control bacterial murein accessi-
bility for phage endolysins and thus they synchronize the
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activity of the holin–lysin system with the late-phase
events of the phage replication cycle [8, 39].
The primary structure of holins is not well conserved in
evolution. However, differences in the amino acid
sequences among holins are not reflected by their function.
Every holin has at least one hydrophobic transmembrane
domain (TMD) as well as C-terminal hydrophilic domain
that carries a high electric charge. There are three classes of
holins. Class I includes proteins that have more than 95
amino acid residues in length. These holins has three
TMDs. Holins belonging to Class I are represented by
Staphylococcus aureus bacteriophage p68 hol15 protein
and Escherichia coli phage k S105 protein. Holins
belonging to class II have 65–95 amino acid residues in
length and they have two TMDs. Lambdoid phage 21 S
protein and Clostridium perfringens bacteriophage A3626
hol3626 protein are members of this class. Class III holins
form only one TMD and are represented by the phage
ACP26F holin [8, 31, 38, 39, 50].
S105, the product of the phage k S gene expression, is
the most widely studied holin. S105 localizes the plasma
membrane and, at a proper time point, it forms lethal
lesions (holes) in lipid bilayer [8]. The average diameter of
membrane holes is more than 340 nm [51].
Phage endolysins are enzymatic proteins responsible for
cell wall degradation [54]. Bacteriophages use them to
hydrolyze the peptidoglycan of the infected bacteria [37].
Endolysins perform activities of endopeptidase, amidase,
glycosidase or lytic transglycosylase to kill bacterial cell by
murein destruction [9, 22, 30]. Acting at the end of the
phage replication cycle, endolysins promote the release of
progeny virions. Endolysins directed against gram-negative
bacteria have different structures from those targeting
gram-positive ones, reflecting differences between enzyme
targets. Gram-negative bacteria are surrounded by the outer
membrane, and therefore the access to the cell wall is
restricted from the outside. It seems to be the reason why
endolysins targeting gram-negative bacteria are small
globular proteins composed of only one domain, called
enzymatically active domain (EAD) [37], whereas endo-
lysins directed against gram-positive microorganisms have
also cell wall binding domain (CBD) [4, 23, 24]. Enzyme
targeting gram-positive bacteria binds to the cell wall
through its CBD and thus remains immobilized on pepti-
doglycan surface. CBD contributes to the hydrolytic effects
of endolysin by synergizing with EAD that performs an
acatalytic function of enzymatic protein. During this pro-
cess, endolysin remains tightly bound to one site of the
peptidoglycan structure [37].
The holin–lysin system is responsible for termination of
the phage infection cycle at a specific time point. The effect
of endolysins on bacterial cell wall is subjected to precise
timing through mechanism explained by the dual-start
model. In this model, the time of bacterial lysis is depen-
dent on the proportion between holin and its antagonist,
antiholin. Both of them are encoded by an open reading
frame. The ratio of holin to antiholin is strictly regulated by
controlling their expression at the translational level. Ele-
vation of the holin–antiholin ratio is followed by the loss of
plasma membrane integrity [39], which allows endolysin to
reach periplasm and begin to degrade the host peptido-
glycan [51].
Interactions Between Bacteriophages and Host
Immune System During Phage Therapy
Phage therapy may carry a risk of immunological reactions,
that is why studies about interactions between phages and
immunity are very important for the rational use of this
treatment. Immune response against bacteriophages
depends on the localization of bacterial infection and the
injection site of therapeutic phages. Under physiological
conditions, some phages are associated with the eukaryotic
component of a gut microbiota and ingested food [35].
High frequency of natural contact of animals/humans with
various types of phages is evidenced by the anti-phage
antibodies detected in the sera of different species (e.g.
human) [44]. Furthermore, an oral administration of phages
during phage therapy of bacterial infection caused by
Staphylococcus, Klebsiella, Escherichia, Proteus and
Pseudomonas induces the production of antibodies as well
[7]. There is no evidence of immunological complications
after the consumption of large amounts of phages [36].
Moreover, the topical applications of phages have not
shown any side effects [57]. A different situation is
observed in the other internal organs and blood stream,
which are not natural environment for phages. Intravenous
administration of bacterial pathogens strongly stimulates
both innate and adaptive immunity [28]. Furthermore,
studies show that phages can penetrate into the circulation,
regardless of the route of administration [7]. If there are no
host bacteria for specific phages, they are rapidly removed
from the blood and internal organs by phagocytic cells
[28]. Moreover, bacterial predators are internalized and
eliminated by cells of the reticuloendothelial system of
liver and spleen. Interestingly, Kupffer cells (specialized
macrophages which are located in the liver) can phagocyte
phages four times faster than spleen macrophages, which
suggests that arrested bacterial pathogens in spleen may
stimulate lymphocytes to produce antibodies [7, 14]. Innate
immunity, known as the first line of defence, is often suf-
ficient to eliminate pathogens before the activation of
adaptive immune response. Studies have shown that
patients subjected to phage therapy were characterized by
the decreasing number of mature neutrophils and the
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increasing number of neutrophil precursors in the periph-
eral blood [55]. These results indicated that phage prepa-
rations can activate innate immune response, which is
helpful in the clearance of bacterial infection. On the other
hand, phages can affect immune cells’ metabolic activities
as well. For instance, studies have shown that bacterio-
phages markedly inhibit ROS production in response to
pathogenic bacteria and suggest that phages decrease
antibacterial innate immunity [32]. However, the relevance
of these findings in relation to clinical situations is
discussed.
During phage therapy, phages are able to induce specific
antibodies (neutralizing antibodies) against them, which
usually inhibit phage effectiveness to lyse the targeted
bacteria in vivo [15, 16, 25, 46]. In fact, neutralizing
antibodies are defined as antibodies that bind epitopes
within those parts of the virion essential for infecting the
host cells [13]. However, it is not clear how long this type
of antibodies will remain in circulation. Concentration of
neutralizing antibodies depends on many aspects, for
instance, (a) the route of phages administration (topical and
oral administration cause a small increase of antibodies)
and (b) the dosage protocol [47]. Studies have shown that
anti-phage neutralizing antibodies are probably one of the
most important factors responsible for the efficacy limita-
tion of phage therapy [44]. However, Sulakvelidze et al.
[46] suggested that the development of neutralizing anti-
bodies should not be a significant problem during the initial
treatment of acute infections, because the kinetics of phage
action are much faster than the host’s production of neu-
tralizing antibodies. Nevertheless, anti-phage antibodies
can be an obstacle if they are still present at the time the
second course of treatment is administered. There are three
ways to solve that problem. It might be envisaged to
(a) repeat phage administration, (b) increase the phage
concentration or (c) use different phages because resistance
is different from one phage to another [46]. Despite the fact
that anti-phage neutralizing antibodies occur during phage
therapy, there is also an increasing level of non-neutraliz-
ing antibodies, IgM and later IgG, and enhancement of
immune response after subsequent injections of some types
of phages [3, 5].
Apart from the humoral immune response, cellular
immunity also plays an important role against phages.
Langbeheim has shown that subcutaneous injection of MS-
2 phages resulted in a strong hypersensitivity reaction in
guinea pigs. Similar results have been obtained in vitro
[21]. However, some other studies indicated that cellular
immune responses play only a slight role in phage inacti-
vation. They showed that the clearance of T7 phage in T
cell-deficient mice was similar to that observed in the wild-
type mice [45]. In view of the contradictory results, this
issue requires further study. Interestingly, some studies
have shown that phages can exert immunosuppressive
activity. Over the study upon the role of bacteriophages in
the development of transplantation tolerance, Go´rski
observed that phages can inhibit the activation of T cells
[17]. Moreover, Kniotek indicated that after phage
administration the humoral immunity is decreased as well
[20].
Altogether results suggest that it is very important to test
the immunological response of every single phage, par-
ticularly if intravenous therapy is being considered. How-
ever, previous clinical and animal trials have not resulted in
serious immunologic reactions during phage therapy [28].
Phage Therapy Now
Bacteriophages have been studied and used to control
bacterial infections of patients in Poland, Georgia and
Russia for nearly a century. Recently, more countries,
including France, Belgium, Switzerland (Phagoburn pro-
ject) and the USA, decided to join [33]. Phage Therapy
Center of the Hirszfeld Institute of Immunology and
Experimental Therapy in Wroclaw offers its patients
experimental therapies against several bacterial diseases,
including those caused by Acinetobacter, Burkholderia,
Citrobacter, Enterobacter, Enterococcus, Escherichia,
Klebsiella, Morganella, Proteus, Pseudomonas, Shigella,
Salmonella, Serratia, Staphylococcus and Steno-
trophomonas. Based on the data published by the Centre,
35–50% of patients treated there got positive therapy
results. So far, the Centre does not offer treatment for
infections caused by Streptococcus spp., Mycobacterium
tuberculosis, Propionibacterium acnes, Borrelia spp.,
Helicobacter pylori, and Haemophilus influenza, nor Ch-
lamydia spp. [19]. As for Eliava Phage Therapy Center in
Tbilisi, phages are used there for the treatment of infections
caused by Enterococcus faecalis of different serovars,
E. coli (O11, O18, O20, O25, O26, O44, O55, O113, O125,
O128), Proteus vulgaris, P. mirabilis, Pseudomonas
aeruginosa, Salmonella (Paratyphi A, Paratyphi B,
Typhimurium, Enteritidis, Heidelberg, Newport, Cholerae
Suis, Oranienburg, Dublin, Anatum), Shigella flexneri
(serovars 1, 2, 3, 4), Sh. sonnei (serovar 6), Sh. newcastle,
Staphylococcus aureus, S. epidermidis, S. saprophyticus,
and Streptococcus pyogenes, S. sanguis, S. salivarius and
more [12]. In order to increase the antimicrobial activity
and to decrease the risk of the phage resistance develop-
ment, each treatment is a cocktail that contains at least a
few bacteriophage strains. Therapy may be executed with
the use of lytic or lysogenic phages. In case of the former,
even though it is a method of choice, there is still a concern
that phage therapy may worsen the health condition of
patients since viral lytic cycle is followed by a release of
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bacterial endotoxins. In contrast, the use of temperate
(lysogenic) phages leaves the possibility of transfer of
virulence genes into so far non-virulent microbionts of
patients. An extensive review over recent bacteriophage
experimental trials has been described elsewhere [53].
Evaluation of phage potential in the treatment of human
infections is an ongoing process. In the year 2016 alone, a
few interesting papers of in vivo experiments on bacte-
riophages have been published. In the first one, a hyper-
variable region of a cell wall protein named PIPEF (phage
infection protein from Enterococcus faecalis) was identi-
fied as a crucial factor of phage tropism for E. faecalis
strains [11]. In vivo testing of phage predation on a gno-
tobiotic mouse model showed that through mutations in
this hypervariable region of PIPEF E. faecalis acquired
phage resistance.
Simultaneously to the mechanisms of acquired phage
resistance in bacteria, possible ways of phage delivery to
specific destinations are being studied. In Singla et al. [40],
different approaches of incorporation of Klebsiella pneu-
moniae phage particles into liposomes as well as biodis-
tribution of liposome-entrapped phages in various organs
of BALB/c mice were evaluated. It turned out that lipo-
some-entrapped phages were a few times more stable in
blood and organs than free phages. These results allowed to
assume that because of longer bioretentivity rates of those
phages in lungs and kidneys, it makes them a suit-
able candidate for the treatment of K. pneumoniae-associ-
ated respiratory tract and urinary tract infections.
Interestingly, phage therapy may be used in a far dif-
ferent manner. Prophylactic use of bacteriophages resem-
bles that described for bacterial probiotics. In essence,
phages administered orally can eliminate diarrheic patho-
gens like Salmonella spp., Clostridium difficile and E. coli.
They can also—if designed to do so—modulate the gas-
trointestinal microbiota composition in a preferred way,
bringing further benefits for the host [1].
Also, phages were used to control the spread of
Campylobacter jejuni and C. coli infections in chickens
[6]. Although C. jejuni does not significantly influence the
wellbeing of chickens, it is a human pathogen that does not
only induce the food poisoning, but is also responsible for
its long-term consequences, i.e. development of Guillain–
Barre syndrome, reactive arthritis and post-infectious irri-
table bowel syndrome [52]. Therefore, decreasing the load
of C. jejuni in poultry products decreases the risk of people
getting sick, and in that sense phage therapy may also be
considered to have an indirect ‘‘probiotic’’ activity. On a
note side, research on the use of phages in other applica-
tions, such as construction of antivenoms (phage display),
and biocontrol in food manufacturing is still ongoing, yet
looks very promising [18, 26, 34].
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